In this video, Annick Desjardins, MD, professor of neurosurgery, professor of neurology and member of the Duke Cancer Institute, explains how clinicians may treat patients with gliomas of different ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

Servier looks like it could bring a second IDH inhibitor from its 2021 takeover of Agios’ oncology business to market, after reporting positive results in a phase 3 brain cancer trial.

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Thanks to last year’s approval of IDH1/2 dual inhibitor Voranigo—which marked the first major treatment advance in low-grade brain cancer in more than two decades—Servier capped off 2024 ...

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...

While genetic screening is not a magic bullet, it has the potential to change the landscape of childhood cancer care in India ...

This metabolite disrupts normal cellular function and promotes tumor growth. Vorasidenib, a novel IDH inhibitor, works by deactivating the mutated IDH1/2 enzymes, halting the production of ...

IDH inhibitors, such as Vorasidenib, represent a major breakthrough for certain gliomas, offering a new option to delay or avoid more intensive treatments. A glioma diagnosis can feel overwhelming for ...